Single‐photon emission computed tomography‐defined active bone marrow‐sparing volumetric‐modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single‐center prospective randomized controlled trial
Cancer · 2023
DOI: 10.1002/cncr.34771 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer, 2023. Verfasst von ShanBing Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the Second People's Hospital of Yibin City, Yibin, Sichuan, China. Hauptthemen laut MEDLINE: Radiotherapy, Intensity-Modulated, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
This study aims to test the efficacy of single‐photon emission computed tomography (SPECT)‐defined active bone marrow‐sparing (ABMS) volumetric‐modulated arc therapy (VMAT) in reducing grade 3+ acute hematologic toxicity (HT) in locally advanced cervical cancer patients treated with chemoradiotherapy.
Methods
This was a prospective, single‐center, open label, randomized clinical trial that enrolled locally advanced cervical cancer patients. Participants were randomized to the 99m Tc sulfur colloid SPECT‐defined ABMS VMAT (ABMS group) or control group, who received weekly cisplatin concurrently with VMAT followed by high–dose‐rate intracavitary brachytherapy. The ABMS group additionally received SPECT‐defined ABM dose constraints. The primary end point was the incidence of grade 3+ acute HT.
Results
A total of 192 Federation of Gynaecology and Obstetrics stage IB‐IIIB patients were randomly treated (96 each in the ABMS control groups). The median follow‐up was 24.0 months. The incidence of grade 3+ acute HT in the ABMS group was significantly lower than that in the control group (32.3% vs. 53.1%, p < .01). The number of patients completing five cycles of cisplatin was 88.5% in the ABMS group and 75% in the control group, and the difference was significant ( p = .02). There were no differences in planning target value coverage, organs at risk dosimetric parameters, 2‐year progression‐free survival, or 2‐year overall survival between the two groups. Patients in the control group had nonsignificantly worse 2‐year distant metastasis than patients in the ABMS group (17.8% vs. 11.1%, p = .19).
Conclusions
ABMS VMAT significantly reduced grade 3+ acute HT and improved chemotherapy delivery compared with the control treatment. We found weak evidence of the effect of ABMS VMAT on distant metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, the Second People's Hospital of Yibin City, Yibin, Sichuan, China.
- Laboratory Medicine, the Second People's Hospital of Yibin City, Yibin, Sichuan, China.
ORCID-Profile: ShanBing Wang
Zitieren
APA
Wang, S., Liu, J., Lei, K., Jia, Y., Wang, C., Zhang, X., & Li, T. (2023). Single‐photon emission computed tomography‐defined active bone marrow‐sparing volumetric‐modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single‐center prospective randomized controlled trial. Cancer. https://doi.org/10.1002/cncr.34771
Vancouver
Wang S, Liu J, Lei K, Jia Y, Wang C, Zhang X, et al. Single‐photon emission computed tomography‐defined active bone marrow‐sparing volumetric‐modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single‐center prospective randomized controlled trial. Cancer. 2023. doi:10.1002/cncr.34771
BibTeX
@article{Wang2023,
author = {Wang, ShanBing and Liu, Jiapei and Lei, Kaijian and Jia, Yuming and Wang, Chunxiu and Zhang, Xia and Li, Ting},
title = {Single‐photon emission computed tomography‐defined active bone marrow‐sparing volumetric‐modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single‐center prospective randomized controlled trial},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34771}
}
EUVIMED